Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M. Buckstein R, et al. Among authors: stempak d. Clin Cancer Res. 2006 Sep 1;12(17):5190-8. doi: 10.1158/1078-0432.CCR-06-0474. Clin Cancer Res. 2006. PMID: 16951238 Clinical Trial.
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma.
Sharp JR, Bouffet E, Stempak D, Gammon J, Stephens D, Johnston DL, Eisenstat D, Hukin J, Samson Y, Bartels U, Tabori U, Huang A, Baruchel S. Sharp JR, et al. Among authors: stempak d. Eur J Cancer. 2010 Dec;46(18):3271-9. doi: 10.1016/j.ejca.2010.06.115. Epub 2010 Jul 23. Eur J Cancer. 2010. PMID: 20656474 Clinical Trial.
Low-dose metronomic chemotherapy: myth or truth?
Baruchel S, Stempak D. Baruchel S, et al. Among authors: stempak d. Onkologie. 2006 Jul;29(7):305-7. doi: 10.1159/000093971. Epub 2006 Jul 3. Onkologie. 2006. PMID: 16874013 Free article. No abstract available.
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J, Bouffet E. Baruchel S, et al. Among authors: stempak d. Eur J Cancer. 2009 Sep;45(13):2352-9. doi: 10.1016/j.ejca.2009.05.008. Epub 2009 Jun 6. Eur J Cancer. 2009. PMID: 19505817 Free article. Clinical Trial.
21 results